InnovaRx Innova Health Strategies

E16.8

Other specified disorders of pancreatic internal secretion

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 1 never code together
E00-E89chapter
Excludes1
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 5
E16.8code
Inclusion terms
  • Increased secretion from endocrine pancreas of growth hormone-releasing hormone
  • Increased secretion from endocrine pancreas of pancreatic polypeptide
  • Increased secretion from endocrine pancreas of somatostatin
  • Increased secretion from endocrine pancreas of vasoactive-intestinal polypeptide
E00-E89chapter
Notes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8E07.0E16-E31E34.-
Index entries leading here 3
  • Hyperplasia, hyperplastic
  • Disorder (of) — see also Disease
    • pancreatic internal secretion E16.9
  • Increase, increased
    • secretion
      • pancreas, endocrine E16.9
        • growth hormone-releasing hormone E16.8
        • pancreatic polypeptide E16.8
        • somatostatin E16.8
        • vasoactive-intestinal polypeptide E16.8
Alongside this code 7 same parent — E16
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

RX08HCC66

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
E16
Block
E15-E16
Siblings
7

Present FY2024–FY2027.